BioCardia, Inc. (BCDA) Insider Trading Activity
NASDAQ$2.74
Market Cap
$13.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
161 of 878
Rank in Industry
96 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BCDA Insider Trading Activity
BCDA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $681,680 | 22 | 96 |
Sells | $6,514 | 1 | 4 |
Related Transactions
| STERTZER SIMON H | director | 4 | $290,513 | 0 | $0 | $290,513 |
| Blank Andrew Scott | director | 1 | $249,999 | 0 | $0 | $249,999 |
| Altman Peter | President and CEO | 14 | $66,170 | 0 | $0 | $66,170 |
| Facteau Bill | director | 1 | $24,999 | 0 | $0 | $24,999 |
| KRASNO RICHARD M | director | 1 | $24,999 | 0 | $0 | $24,999 |
| McClung David | Chief Financial Officer | 1 | $24,999 | 0 | $0 | $24,999 |
| GILLIS EDWARD M | Senior Vice President, Devices | 0 | $0 | 1 | $6,514 | $-6,514 |
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Insider Activity of BioCardia, Inc.
Over the last 12 months, insiders at BioCardia, Inc. have bought $681,680 and sold $6,514 worth of BioCardia, Inc. stock.
On average, over the past 5 years, insiders at BioCardia, Inc. have bought $525,051 and sold $31,164 worth of stock each year.
Highest buying activity among insiders over the last 12 months: STERTZER SIMON H (director) — $290,513. Blank Andrew Scott (director) — $249,999. Altman Peter (President and CEO) — $66,170.
The last purchase of 131,233 shares for transaction amount of $249,999 was made by Blank Andrew Scott (director) on 2025‑04‑23.
List of Insider Buy and Sell Transactions, BioCardia, Inc.
| 2025-04-23 | Blank Andrew Scott | director | 131,233 2.8751% | $1.91 | $249,999 | +43.68% | ||
| 2025-04-23 | Altman Peter | President and CEO | 26,246 0.575% | $1.91 | $49,999 | +43.68% | ||
| 2025-04-23 | STERTZER SIMON H | director | 104,986 2.3% | $1.91 | $199,998 | +43.68% | ||
| 2025-04-23 | McClung David | Chief Financial Officer | 13,123 0.2875% | $1.91 | $24,999 | +43.68% | ||
| 2025-04-23 | KRASNO RICHARD M | director | 13,123 0.2875% | $1.91 | $24,999 | +43.68% | ||
| 2025-04-23 | Facteau Bill | director | 13,123 0.2875% | $1.91 | $24,999 | +43.68% | ||
| 2025-04-15 | Altman Peter | President and CEO | 100 0.0023% | $2.14 | $214 | +20.00% | ||
| 2025-04-11 | Altman Peter | President and CEO | 300 0.0066% | $2.03 | $609 | +23.48% | ||
| 2025-04-10 | Altman Peter | President and CEO | 300 0.0064% | $1.99 | $597 | +23.96% | ||
| 2025-04-07 | Altman Peter | President and CEO | 500 0.0105% | $1.96 | $980 | +3.02% | ||
| 2025-04-04 | Altman Peter | President and CEO | 800 0.0173% | $2.04 | $1,632 | +0.99% | ||
| 2025-04-03 | Altman Peter | President and CEO | 1,200 0.0274% | $2.24 | $2,688 | -4.29% | ||
| 2025-03-05 | STERTZER SIMON H | director | 1,000 0.0211% | $2.45 | $2,450 | +0.20% | ||
| 2025-03-04 | STERTZER SIMON H | director | 15,536 0.3105% | $2.30 | $35,733 | +0.79% | ||
| 2025-03-03 | Altman Peter | President and CEO | 500 0.009% | $2.11 | $1,055 | -0.78% | ||
| 2025-03-03 | STERTZER SIMON H | director | 22,753 0.4459% | $2.30 | $52,332 | -0.78% | ||
| 2025-02-07 | Altman Peter | President and CEO | 600 0.0132% | $2.48 | $1,488 | +6.33% | ||
| 2025-01-30 | Altman Peter | President and CEO | 239 0.0052% | $2.38 | $569 | +8.19% | ||
| 2025-01-29 | Altman Peter | President and CEO | 500 0.0115% | $2.40 | $1,200 | +5.25% | ||
| 2024-12-23 | Altman Peter | President and CEO | 1,000 0.0218% | $2.06 | $2,060 | +17.91% |
Total: 170
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Blank Andrew Scott | director | 265957 5.2205% | $728,722.18 | 2 | 0 | +44.98% |
| Altman Peter | President and CEO | 138966 2.7278% | $380,766.84 | 75 | 0 | <0.0001% |
| STERTZER SIMON H | director | 120365 2.3627% | $329,800.10 | 22 | 0 | +44.98% |
| McClung David | Chief Financial Officer | 43131 0.8466% | $118,178.94 | 7 | 0 | |
| KRASNO RICHARD M | director | 16268 0.3193% | $44,574.32 | 1 | 0 | |
| Facteau Bill | director | 13123 0.2576% | $35,957.02 | 1 | 0 | |
| GILLIS EDWARD M | Senior Vice President, Devices | 8968 0.176% | $24,572.32 | 0 | 1 | |
| Brooks Andrew A | CEO | 63560031 1247.6352% | $174.15M | 11 | 0 | |
| BROOKS JONATHAN | director, 10 percent owner | 32045292 629.0248% | $87.8M | 1 | 2 | |
| FROST PHILLIP MD ET AL | 10 percent owner | 1896025 37.2175% | $5.2M | 19 | 2 | |
| Allen Jim L. | director | 668200 13.1163% | $1.83M | 1 | 0 | +44.98% |
| Morgan Thomas H. | director | 40419 0.7934% | $110,748.06 | 3 | 8 | |
| GERAGHTY KENNETH G | director, 10 percent owner | 6221 0.1221% | $17,045.54 | 2 | 0 | |
| GOTTLIEB CORREY J | director | 3333 0.0654% | $9,132.42 | 1 | 0 | |
| MERCORELLA ANTHONY J | director | 333 0.0065% | $912.42 | 1 | 0 | |
| GERSTENBLATT RANDY | director | 66 0.0013% | $180.84 | 1 | 0 | |
| ISRAEL ROY | Chairman,CEO & President | 0 0% | $0 | 0 | 3 | |
| GIULIANI RHEAUME PATRICIA A | VP, CFO & Treasurer | 0 0% | $0 | 0 | 1 | |
| SPECHT WILLEM F | director | 0 0% | $0 | 0 | 1 | |
| Good Kenneth W | director, 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Richards Ronald N. | director | 0 0% | $0 | 1 | 1 | |
| Kvitnitsky Mikhail | 10 percent owner | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$1,848,072 | 66 | -14.67% | $12.86M | |
$85,897,100 | 36 | 2.47% | $16.32M | |
$226,127 | 22 | -27.62% | $14.05M | |
$555,628 | 21 | 43.52% | $15.36M | |
$547,862 | 19 | -29.82% | $13.36M | |
$112,810,270 | 18 | -1.20% | $12.9M | |
$37,194,483 | 17 | -51.30% | $13.23M | |
$2,553,853 | 17 | 16.69% | $13.93M | |
$122,973 | 15 | -26.96% | $14.28M | |
$1,199,157 | 14 | 7.52% | $12.94M | |
BioCardia, Inc. (BCDA) | $941,975 | 12 | -10.74% | $13.96M |
$389,864 | 11 | 12.52% | $15.12M | |
$70,584,874 | 10 | 3.97% | $16.58M | |
$36,538,405 | 10 | -21.99% | $16.69M | |
$2,891,537 | 8 | -39.31% | $13.66M | |
$2,060,158 | 5 | -21.35% | $15.71M | |
$1,028,395 | 4 | -11.91% | $14.52M | |
$31,190 | 2 | -14.18% | $12.87M | |
$5,512,500 | 1 | -7.91% | $12.58M |
BCDA Institutional Investors: Active Positions
| Increased Positions | 7 | +58.33% | 127,007 | +100.4% |
| Decreased Positions | 4 | -33.33% | 27,541 | -21.77% |
| New Positions | 4 | New | 56,770 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 15 | +25% | 225,963 | +78.63% |
BCDA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Susquehanna International Group, Llp | $117.00 | 0.88% | 43,842 | -26,754 | -37.9% | 2024-12-31 |
| Brown Advisory Inc | $95.00 | 0.71% | 35,538 | +35,538 | New | 2025-03-31 |
| Geode Capital Management, Llc | $83.00 | 0.62% | 30,987 | +16,251 | +110.28% | 2024-12-31 |
| Cm Management, Llc | $67.00 | 0.5% | 25,000 | +25,000 | New | 2024-12-31 |
| Vanguard Group Inc | $35.00 | 0.26% | 12,884 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $13.00 | 0.1% | 4,750 | +4,750 | New | 2024-12-31 |
| Morgan Stanley | $11.00 | 0.08% | 4,016 | +3,986 | +13,286.67% | 2024-12-31 |
| Pingora Partners Llc | $3.00 | 0.02% | 1,036 | 0 | 0% | 2024-12-31 |
| Jpmorgan Chase & Co | $2.00 | 0.02% | 899 | +899 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 535 | -747 | -58.27% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.